Prevention and Immunotherapy of Secondary Murine Alveolar Echinococcosis Employing Recombinant EmP29 Antigen.
Alveolar echinococcosis (AE) is caused by infection with the larval stage of the tapeworm Echinococcus multilocularis. An increasing understanding of immunological events that account for the metacestode survival in human and murine AE infection prompted us to undertake explorative experiments tackl...
Main Authors: | Ghalia Boubaker, Andrew Hemphill, Cristina Olivia Huber, Markus Spiliotis, Hamouda Babba, Bruno Gottstein |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC4460070?pdf=render |
Similar Items
-
Echinococcus P29 antigen: molecular characterization and implication on post-surgery follow-up of CE patients infected with different species of the Echinococcus granulosus complex.
by: Ghalia Boubaker, et al.
Published: (2014-01-01) -
Subcutaneous infection model facilitates treatment assessment of secondary Alveolar echinococcosis in mice.
by: Tatiana Küster, et al.
Published: (2013-01-01) -
Treatment of echinococcosis: albendazole and mebendazole – what else?
by: Hemphill Andrew, et al.
Published: (2014-01-01) -
Screening of the Open Source Malaria Box Reveals an Early Lead Compound for the Treatment of Alveolar Echinococcosis.
by: Britta Stadelmann, et al.
Published: (2016-03-01) -
Elevated incidence of alveolar echinococcosis in immunocompromised patients
by: A. Lachenmayer, et al.
Published: (2019-09-01)